Skip to main content
Erschienen in: Lung 1/2017

19.11.2016

Identification of Key Cost Generating Events for Idiopathic Pulmonary Fibrosis: A Systematic Review

verfasst von: Shalvaree Vaidya, Clare L. Hibbert, Elizabeth Kinter, Stefan Boes

Erschienen in: Lung | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Idiopathic pulmonary fibrosis (IPF) is an incurable, debilitating disease which impairs lung function and eventually leads to death. Currently, there is a lack of effective modifying therapies and treatments for IPF as the underlying epidemiological mechanism is not clearly understood. This leads to difficulty in diagnosing and managing IPF, which results in a high incurment of disease-associated cost. Even though IPF poses a substantial economic burden, there is a lack of research available on cost triggers and healthcare utilization, which can be a barrier to future economic evaluations of new medicines for IPF.

Objectives

We aimed to conduct a systematic literature review (SLR) to identify the key cost-generating events of IPF and to gather any related costing information.

Results

The data showed that the main events triggering high resource use in patients were the symptoms of IPF progression along with comorbidities and lung transplantations. These events result in a high economic impact through the use of medications, health care professionals, and hospital stays.

Conclusion

More research is needed to identify the direct, and indirect, relationships between IPF events and the costs they generate. This would help to further evaluate the area of need for future health technologies and to understand what events should be targeted to reduce the global economic burden of IPF.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Loveman E, Copley VR, Colquitt J, Scott DA, Clegg A, Jones J, O’Reilly KM, Singh S, Bausewein C, Wells A (2015) The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation. Health Technol Assess 19:1–336 i–xxivCrossRefPubMedPubMedCentral Loveman E, Copley VR, Colquitt J, Scott DA, Clegg A, Jones J, O’Reilly KM, Singh S, Bausewein C, Wells A (2015) The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation. Health Technol Assess 19:1–336 i–xxivCrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Panos RJ, Mortenson RL, Niccoli SA, King TE Jr (1990) Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 88:396–404CrossRefPubMed Panos RJ, Mortenson RL, Niccoli SA, King TE Jr (1990) Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 88:396–404CrossRefPubMed
3.
Zurück zum Zitat Collard HR, Ward AJ, Lanes S, Cortney Hayflinger D, Rosenberg DM, Hunsche E (2012) Burden of illness in idiopathic pulmonary fibrosis. J Med Econ 15:829–835CrossRefPubMed Collard HR, Ward AJ, Lanes S, Cortney Hayflinger D, Rosenberg DM, Hunsche E (2012) Burden of illness in idiopathic pulmonary fibrosis. J Med Econ 15:829–835CrossRefPubMed
4.
Zurück zum Zitat Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier J-F, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824CrossRefPubMed Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier J-F, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824CrossRefPubMed
5.
Zurück zum Zitat Kistler KD, Nalysnyk L, Rotella P, Esser D (2014) Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med 14:1–12CrossRef Kistler KD, Nalysnyk L, Rotella P, Esser D (2014) Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med 14:1–12CrossRef
6.
Zurück zum Zitat Lee AS, Mira-Avendano I, Ryu JH, Daniels CE (2014) The burden of idiopathic pulmonary fibrosis: an unmet public health need. Respir Med 108:955–967CrossRefPubMed Lee AS, Mira-Avendano I, Ryu JH, Daniels CE (2014) The burden of idiopathic pulmonary fibrosis: an unmet public health need. Respir Med 108:955–967CrossRefPubMed
7.
Zurück zum Zitat Hutchinson J, Fogarty A, Hubbard R, McKeever T (2015) Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 46:795–806CrossRefPubMed Hutchinson J, Fogarty A, Hubbard R, McKeever T (2015) Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 46:795–806CrossRefPubMed
8.
Zurück zum Zitat Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100CrossRefPubMedPubMedCentral Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Johnston K, Buxton M, Jones D, Fitzpatrick R (1999) Assessing the costs of healthcare technologies in clinical trials. Health Technol Assess, vol. 3 Johnston K, Buxton M, Jones D, Fitzpatrick R (1999) Assessing the costs of healthcare technologies in clinical trials. Health Technol Assess, vol. 3
10.
Zurück zum Zitat Boccuzzi SJ (2003) Indirect health care costs. In: Weintraub WS (ed) Cardiovascular health care economics. Humana Press, Totowa, NJ, pp 63–79CrossRef Boccuzzi SJ (2003) Indirect health care costs. In: Weintraub WS (ed) Cardiovascular health care economics. Humana Press, Totowa, NJ, pp 63–79CrossRef
11.
Zurück zum Zitat Statistics, B.o.L. (2015) Consumer price index-all urban consumers Statistics, B.o.L. (2015) Consumer price index-all urban consumers
12.
Zurück zum Zitat Collard HR, Chen SY, Yeh WS, Li Q, Lee YC, Wang A, Raghu G (2015) Health care utilization and costs in idiopathic pulmonary fibrosis in United States medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc 12:981–987CrossRefPubMed Collard HR, Chen SY, Yeh WS, Li Q, Lee YC, Wang A, Raghu G (2015) Health care utilization and costs in idiopathic pulmonary fibrosis in United States medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc 12:981–987CrossRefPubMed
13.
Zurück zum Zitat NICE (2013) Idiopathic pulmonary fibrosis costing report. National Institute for Health and Care Excellence, Manchester NICE (2013) Idiopathic pulmonary fibrosis costing report. National Institute for Health and Care Excellence, Manchester
14.
Zurück zum Zitat Loveman E, Copley VR, Colquitt JL, Scott DA, Clegg AJ, Jones J, O’Reilly KM, Singh S, Bausewein C, Wells A (2014) The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol 15:63CrossRefPubMedPubMedCentral Loveman E, Copley VR, Colquitt JL, Scott DA, Clegg AJ, Jones J, O’Reilly KM, Singh S, Bausewein C, Wells A (2014) The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol 15:63CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Lee JS, McLaughlin S, Collard HR (2011) Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med 17:348–354CrossRefPubMed Lee JS, McLaughlin S, Collard HR (2011) Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med 17:348–354CrossRefPubMed
16.
Zurück zum Zitat Chen S-Y, Collard HR, Yeh W-S, Li Q, Lee Y-C, Wang A, Raghu G, International B Francisco U.o.C.S. and Evidera (2014) An analysis of US medicare beneficiaries: Burden of direct medical costs in patients with idiopathic pulmonary fibrosis. In: ISPOR 17th Annual European Congress, Amsterdam, The Netherlands Chen S-Y, Collard HR, Yeh W-S, Li Q, Lee Y-C, Wang A, Raghu G, International B Francisco U.o.C.S. and Evidera (2014) An analysis of US medicare beneficiaries: Burden of direct medical costs in patients with idiopathic pulmonary fibrosis. In: ISPOR 17th Annual European Congress, Amsterdam, The Netherlands
17.
Zurück zum Zitat Chen SY, Collard HR, Yeh WS, Li Q, Lee YC, Wang A, Raghu G (2014) PRS26—an analysis of US medicare beneficiaries: burden of direct medical costs in patients with idiopathic pulmonary fibrosis. Value Health 17:A592CrossRefPubMed Chen SY, Collard HR, Yeh WS, Li Q, Lee YC, Wang A, Raghu G (2014) PRS26—an analysis of US medicare beneficiaries: burden of direct medical costs in patients with idiopathic pulmonary fibrosis. Value Health 17:A592CrossRefPubMed
18.
Zurück zum Zitat Wilson EC, Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Twentyman OP, Wilson AM (2014) Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial. Pharmacoeconomics 32:87–99CrossRefPubMed Wilson EC, Shulgina L, Cahn AP, Chilvers ER, Parfrey H, Clark AB, Twentyman OP, Wilson AM (2014) Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: an economic evaluation alongside a randomised controlled trial. Pharmacoeconomics 32:87–99CrossRefPubMed
19.
Zurück zum Zitat Wu N, Yu YF, Chuang CC, Wang R, Benjamin NN, Coultas DB (2015) Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States. J Med Econ 18:249–257CrossRefPubMed Wu N, Yu YF, Chuang CC, Wang R, Benjamin NN, Coultas DB (2015) Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States. J Med Econ 18:249–257CrossRefPubMed
20.
Zurück zum Zitat George TJ, Arnaoutakis GJ, Shah AS (2011) LUng transplant in idiopathic pulmonary fibrosis. Arch Surg 146:1204–1209CrossRefPubMed George TJ, Arnaoutakis GJ, Shah AS (2011) LUng transplant in idiopathic pulmonary fibrosis. Arch Surg 146:1204–1209CrossRefPubMed
21.
22.
Zurück zum Zitat Nathan SD, Noble PW, Tuder RM (2007) Idiopathic pulmonary fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 175:875–880CrossRefPubMed Nathan SD, Noble PW, Tuder RM (2007) Idiopathic pulmonary fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 175:875–880CrossRefPubMed
23.
Zurück zum Zitat Lancaster LH, Mason WR, Parnell JA, Rice TW, Loyd JE, Milstone AP, Collard HR, Malow BA (2009) Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 136:772–778CrossRefPubMedPubMedCentral Lancaster LH, Mason WR, Parnell JA, Rice TW, Loyd JE, Milstone AP, Collard HR, Malow BA (2009) Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest 136:772–778CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Zhuo X, Zhang P, Hoerger TJ (2013) Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med 45:253–261CrossRefPubMed Zhuo X, Zhang P, Hoerger TJ (2013) Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med 45:253–261CrossRefPubMed
25.
Zurück zum Zitat Excellence, N.I.f.H.a.C. (2015) Nintedanib for treating idiopathic pulmonary fibrosis NICE Excellence, N.I.f.H.a.C. (2015) Nintedanib for treating idiopathic pulmonary fibrosis NICE
26.
Zurück zum Zitat Eliot O-T, Yanxin W, Bonni H, Hongwei W, Juliette M (2012) the economic burden of idiopathic pulmonary fibrosis from diagnosis to lung transplant. In: A40, the economic burden of respiratory disease and cost-effectiveness of treatments, American Thoracic Society, pp A1497–A1497 Eliot O-T, Yanxin W, Bonni H, Hongwei W, Juliette M (2012) the economic burden of idiopathic pulmonary fibrosis from diagnosis to lung transplant. In: A40, the economic burden of respiratory disease and cost-effectiveness of treatments, American Thoracic Society, pp A1497–A1497
27.
Zurück zum Zitat Hagaman JT, Kinder BW, Eckman MH (2010) Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung 188:125–132CrossRefPubMed Hagaman JT, Kinder BW, Eckman MH (2010) Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung 188:125–132CrossRefPubMed
28.
Zurück zum Zitat Tzouvelekis A, Bonella F, Spagnolo P (2015) Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag 11:359–370PubMedPubMedCentral Tzouvelekis A, Bonella F, Spagnolo P (2015) Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag 11:359–370PubMedPubMedCentral
29.
Zurück zum Zitat Excellence N.I.f.H.a.C (2013) Pirfenidone for treating idiopathic pulmonary fibrosis. In: Final appraisal determination, NICE Excellence N.I.f.H.a.C (2013) Pirfenidone for treating idiopathic pulmonary fibrosis. In: Final appraisal determination, NICE
30.
Zurück zum Zitat Ferreira LM (2014) Two new IPF treatments will reportedly will cost between $94 K and $96 K a year Ferreira LM (2014) Two new IPF treatments will reportedly will cost between $94 K and $96 K a year
Metadaten
Titel
Identification of Key Cost Generating Events for Idiopathic Pulmonary Fibrosis: A Systematic Review
verfasst von
Shalvaree Vaidya
Clare L. Hibbert
Elizabeth Kinter
Stefan Boes
Publikationsdatum
19.11.2016
Verlag
Springer US
Erschienen in
Lung / Ausgabe 1/2017
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-016-9960-6

Weitere Artikel der Ausgabe 1/2017

Lung 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.